Biologics-Focused FDA Panel to Review Johnson & Johnson and Legend Biotech Supplemental Applications
Silver Spring, Maryland – The FDA’s Oncologic Drugs Advisory Committee will convene on Friday, March 15th to review Johnson & Johnson and Legend Biotech Corporation’s supplemental biologics license application for Carvykti, a treatment for relapsed or refractory multiple myeloma patients. The primary focus of the meeting will be to evaluate the risk-benefit assessment of ciltacabtagene-autoleucel … Read more